UBS Group set a $71.00 price objective on Colgate-Palmolive (NYSE:CL) in a report published on Wednesday, www.stocktargetadvisor.com reports. The brokerage currently has a buy rating on the stock.

A number of other research analysts have also commented on the company. Argus reaffirmed a buy rating and set a $75.00 price target (up previously from $72.00) on shares of Colgate-Palmolive in a research report on Tuesday, September 18th. Zacks Investment Research raised Colgate-Palmolive from a sell rating to a hold rating in a research report on Tuesday, September 18th. Atlantic Securities started coverage on Colgate-Palmolive in a research report on Thursday, September 20th. They set a neutral rating and a $71.00 price target for the company. Macquarie lowered Colgate-Palmolive from an outperform rating to a neutral rating and lowered their price target for the company from $74.00 to $65.00 in a research report on Monday, July 30th. Finally, ValuEngine raised Colgate-Palmolive from a sell rating to a hold rating in a research report on Tuesday, July 31st. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have given a buy rating to the company. Colgate-Palmolive presently has an average rating of Hold and an average price target of $70.79.

CL opened at $64.52 on Wednesday. The company has a market cap of $54.36 billion, a price-to-earnings ratio of 22.48, a price-to-earnings-growth ratio of 2.87 and a beta of 0.72. The company has a debt-to-equity ratio of -34.49, a current ratio of 1.06 and a quick ratio of 0.74. Colgate-Palmolive has a one year low of $61.28 and a one year high of $77.91.

Colgate-Palmolive (NYSE:CL) last released its quarterly earnings results on Friday, July 27th. The company reported $0.77 EPS for the quarter, meeting analysts’ consensus estimates of $0.77. The business had revenue of $3.89 billion during the quarter, compared to analyst estimates of $3.91 billion. Colgate-Palmolive had a return on equity of 2,494.79% and a net margin of 13.97%. Colgate-Palmolive’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.72 EPS. Equities research analysts forecast that Colgate-Palmolive will post 2.99 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, November 15th. Shareholders of record on Friday, October 19th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, October 18th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 2.60%. Colgate-Palmolive’s dividend payout ratio (DPR) is 58.54%.

In other Colgate-Palmolive news, VP Philip G. Shotts sold 462 shares of the company’s stock in a transaction that occurred on Tuesday, September 11th. The stock was sold at an average price of $67.05, for a total transaction of $30,977.10. Following the transaction, the vice president now owns 41,250 shares in the company, valued at approximately $2,765,812.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Vice Chairman Dennis J. Hickey sold 120,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 14th. The stock was sold at an average price of $65.72, for a total value of $7,886,400.00. Following the transaction, the insider now owns 202,414 shares in the company, valued at approximately $13,302,648.08. The disclosure for this sale can be found here. Insiders have sold a total of 395,779 shares of company stock worth $26,108,856 in the last quarter. Company insiders own 1.02% of the company’s stock.

Several hedge funds have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA grew its stake in shares of Colgate-Palmolive by 11.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 32,560,326 shares of the company’s stock worth $2,110,235,000 after buying an additional 3,397,667 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Colgate-Palmolive by 8.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 20,135,385 shares of the company’s stock worth $1,304,974,000 after buying an additional 1,596,825 shares during the last quarter. OppenheimerFunds Inc. grew its stake in shares of Colgate-Palmolive by 6.4% in the 2nd quarter. OppenheimerFunds Inc. now owns 6,785,987 shares of the company’s stock worth $439,801,000 after buying an additional 405,430 shares during the last quarter. Fiera Capital Corp grew its stake in shares of Colgate-Palmolive by 4.6% in the 2nd quarter. Fiera Capital Corp now owns 5,012,573 shares of the company’s stock worth $324,865,000 after buying an additional 219,925 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec grew its stake in shares of Colgate-Palmolive by 15.3% in the 2nd quarter. Caisse DE Depot ET Placement DU Quebec now owns 4,093,312 shares of the company’s stock worth $265,288,000 after buying an additional 543,500 shares during the last quarter. Hedge funds and other institutional investors own 74.95% of the company’s stock.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, and other related products.

Featured Story: Treasury Bonds

Analyst Recommendations for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.